European Investor
18 Aug 2026, 18:06
Veeva Systems Stock Rises 3.1% as Barclays Raises Price Target to $275
Veeva Systems (NYSE: VEEV) shares are up 3.1% after Barclays raised its price target on the cloud software company, providing a positive catalyst as the firm maintained its Overweight rating.
Barclays analyst Saket Kalia increased the price target for Veeva Systems from $235 to $275. With Veeva trading around $245.65, the new target implies approximately 12% upside.
Why the Barclays Target Increase Is Positive for Veeva
The size of the revision is notable. Barclays lifted its target by $40, or roughly 17%, while retaining its bullish Overweight recommendation. The new $275 target is also comfortably above the stock's price in the report, indicating that Barclays continues to see additional upside even after today's 3.1% gain.
Veeva occupies a distinctive position within the enterprise software sector because of its specialization in cloud applications for the life sciences industry. Its products support pharmaceutical and biotechnology companies across areas including clinical development, regulatory processes, quality management, safety, medical affairs and commercial operations.
This vertical specialization creates a relatively strong competitive position. Life sciences customers operate in highly regulated environments, making industry-specific software, data management and regulatory capabilities particularly important. Once these systems become embedded in customers' workflows, switching providers can also become operationally complex.
## AI and Life Sciences Software Provide Longer-Term Growth Opportunities
Veeva is also positioned at the intersection of enterprise software, healthcare technology and the broader digital transformation of pharmaceutical development. Increasing use of data analytics and AI across drug development and commercial operations could expand demand for integrated cloud platforms capable of managing increasingly complex life-sciences workflows and data.
Unlike more general enterprise software companies, Veeva's concentration on life sciences gives investors relatively direct exposure to technology spending within pharmaceutical and biotechnology companies.
Barclays' decision to raise its target from $235 to $275 while maintaining an Overweight rating reinforces that growth thesis. With the new target implying about 12% upside from $245.65, the analyst action appears to be a key factor supporting Veeva Systems shares today.
Veeva Systems (NYSE: VEEV) shares are up 3.1% after Barclays raised its price target on the cloud software company, providing a positive catalyst as the firm maintained its Overweight rating.
Barclays analyst Saket Kalia increased the price target for Veeva Systems from $235 to $275. With Veeva trading around $245.65, the new target implies approximately 12% upside.
Why the Barclays Target Increase Is Positive for Veeva
The size of the revision is notable. Barclays lifted its target by $40, or roughly 17%, while retaining its bullish Overweight recommendation. The new $275 target is also comfortably above the stock's price in the report, indicating that Barclays continues to see additional upside even after today's 3.1% gain.
Veeva occupies a distinctive position within the enterprise software sector because of its specialization in cloud applications for the life sciences industry. Its products support pharmaceutical and biotechnology companies across areas including clinical development, regulatory processes, quality management, safety, medical affairs and commercial operations.
This vertical specialization creates a relatively strong competitive position. Life sciences customers operate in highly regulated environments, making industry-specific software, data management and regulatory capabilities particularly important. Once these systems become embedded in customers' workflows, switching providers can also become operationally complex.
## AI and Life Sciences Software Provide Longer-Term Growth Opportunities
Veeva is also positioned at the intersection of enterprise software, healthcare technology and the broader digital transformation of pharmaceutical development. Increasing use of data analytics and AI across drug development and commercial operations could expand demand for integrated cloud platforms capable of managing increasingly complex life-sciences workflows and data.
Unlike more general enterprise software companies, Veeva's concentration on life sciences gives investors relatively direct exposure to technology spending within pharmaceutical and biotechnology companies.
Barclays' decision to raise its target from $235 to $275 while maintaining an Overweight rating reinforces that growth thesis. With the new target implying about 12% upside from $245.65, the analyst action appears to be a key factor supporting Veeva Systems shares today.
